Blueprint Medicines Corp (2L9)

Currency in EUR
110.0500
0.0000(0.00%)
Delayed Data·
Showing Blueprint Medicines Corp historical data. For real-time data please try another search
Fair Value
Day's Range
109.9500110.0500
52 wk Range
67.5400113.0000
Key Statistics
Bid/Ask
109.95 / 113.30
Prev. Close
110.05
Open
110
Day's Range
109.95-110.05
52 wk Range
67.54-113
Volume
-
Average Volume (3m)
70
1-Year Change
12.04%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2L9 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Currently not supported.

Blueprint Medicines Corp News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Blueprint Medicines Corp Company Profile

Blueprint Medicines Corporation operates as a global biopharmaceutical company that develops medicines for genomically defined cancers, blood disorders, and allergy/inflammation in the United States and internationally. The company develops AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company develops BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. Blueprint Medicines Corporation was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. The company was incorporated in 2008 and is based in Cambridge, Massachusetts. As of July 18, 2025, Blueprint Medicines Corporation operates as a subsidiary of Sanofi.

Compare 2L9 to Peers and Sector

Metrics to compare
2L9
Peers
Sector
Relationship
P/E Ratio
−53.8x0.0x−0.5x
PEG Ratio
−1.110.000.00
Price/Book
24.5x0.0x2.6x
Price / LTM Sales
14.9x0.0x3.3x
Upside (Analyst Target)
-0.0%42.4%
Fair Value Upside
Unlock0.0%7.2%Unlock

Earnings

Latest Release
May 01, 2025
EPS / Forecast
0.01 / --
Revenue / Forecast
149.41M / --
EPS Revisions
Last 90 days

2L9 Income Statement

People Also Watch

51.12
DIOD
-0.93%
29.74
YOU
+0.34%
53.33
ALK
-1.51%
75.29
ECG
+1.61%
11.22
PACS
-2.69%
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.